IDH1 and glioblastoma: Predictions on all REMBRANDT patients with model confidence greater than 70% show that predicted IDH-wildtype glioma, regardless of tumor histological grade, have similar survival trajectories and median overall survival (OS = 1.1 years) as IDH-wildtype glioblastomas in the TCGA (OS = 1.2 years) (Fig. 6A).